Intuitive Surgical reported strong Q2 2026 results with significant revenue and procedure growth, driven by global adoption of its Da Vinci and Ion platforms. Despite some moderation in US procedure growth and challenges in China, the company maintains a positive outlook for Da Vinci procedure growth in 2026, indicating continued market expansion and innovation.
Intuitive Surgical's Q2 2026 earnings call transcript reveals a robust financial performance with a 19% increase in revenue and 16% growth in total procedures. This indicates strong demand for its robotic-assisted surgical platforms, particularly the Da Vinci and Ion systems, which saw significant global adoption. While the company noted some moderation in US procedure growth and persistent challenges in China due to competition and pricing pressures, the overall outlook for Da Vinci procedure growth remains strong at 13.5% to 15.5% for 2026. This positive performance and outlook are significant for investors, signaling continued market leadership and innovation in the robotic surgery space, despite regional headwinds.